2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2579

A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Abstract Number: 2580

Pharmacotherapies Targeting Type 2 SLE Symptoms
Abstract Number: 2581

Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Abstract Number: 2582

Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test : A Systematic Review and Meta-analysis
Abstract Number: 2583

Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies
Abstract Number: 2584

Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
Abstract Number: 2585

A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus
Abstract Number: 2586

Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome
Abstract Number: 2587

Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis
Abstract Number: 2588

Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations
Abstract Number: 2589

Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index
Abstract Number: 2590

Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis
Abstract Number: 2591

Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)
Abstract Number: 2592

Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care
Abstract Number: 2593

Cyclophosphamide for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].